39070-14-9
[1]JournalofMedicinalChemistry,2008,vol.51,p.2412-2420
[2]Patent:WO2007/2931,2007,A2.Locationinpatent:Page/Pagecolumn76;124-125
[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487
[1]Actapoloniaepharmaceutica,2013,vol.70,p.481-487
Title: Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Journal: Cancer chemotherapy and pharmacology 20120301
Title: Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
Journal: Anti-cancer drugs 20120201
Title: The effect of N-acetylcysteine on the antitumor activity of ifosfamide.
Journal: Canadian journal of physiology and pharmacology 20110501
Title: Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Journal: Kidney international 20061101
Title: [Identification of glufosfamide metabolites in rats].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20060601
Title: Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.
Journal: Cancer chemotherapy and pharmacology 20050201
Title: 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.
Journal: Chemical research in toxicology 20040901
Title: Phosphate prodrugs of isophosphoramide mustard.
Journal: Acta poloniae pharmaceutica 20030101
Title: Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Journal: Acta biochimica Polonica 20020101
Title: Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?
Journal: Cancer treatment and research 20020101
Title: Identification of new aqueous chemical degradation products of isophosphoramide mustard.
Journal: Journal of pharmaceutical and biomedical analysis 20010601
Title: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Journal: Lancet (London, England) 19800927
Title: Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40.
Title: Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
